Atiprimod dihydrochloride

N/A

Report date: 2022/11/25 17:29:07
NME

Base Information

Drug NameAtiprimod dihydrochloride
Drug Alias Nameatiprimodum阿替莫德盐酸盐Atiprimod hydrochloride盐酸阿替莫德阿替莫德 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-6 modulatorsSignal transducer and activator of transcription 3 inhibitors
TargetsInterleukin-6Signal transducer and activator of transcription 3
Therapy Area/IndicationsMultiple MyelomaCarcinoma, NeuroendocrineNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterCallisto Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaCarcinoma, NeuroendocrineNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG